BofA Securities analyst Alec W. Stranahan lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $83.00 (from $86.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE